Malaria, which is transmitted by anopheline mosquitoes, is an enormous public health problem worldwide and every year kills 1 to 2 million people, mostly children residing in Africa. Clearly, an effective vaccine for the control of malaria is urgently needed.
The 42-kDa carboxyl terminus of merozoite surface protein 1 (MSP1 42 ) is a leading malaria vaccine candidate. In a murine model, vaccination with the 19-kDa carboxyl terminus of Plasmodium yoelii MSP1 (PyMSP1 19 ) confers protection against challenge, and the protective immunity correlates with the high titer of PyMSP1 19 -specific antibodies (6, 15) . Despite its promising potential, none of the MSP1-based Plasmodium falciparum vaccine candidates have shown satisfactory outcomes in human clinical trials. With current antigen-adjuvant formulations, it has been difficult to induce robust antibody responses in humans (18) . Besides the poor immunogenicity, polymorphisms in the P. falciparum msp1 gene are thought to represent another big obstacle for the development of vaccines based on this molecule (24, 29) .
Are poor immunogenicity and gene polymorphism really the main reasons why the MSP1-based vaccine candidates in human phase II trials are much less effective than those in animal models? In a murine model, immunization with recombinant PyMSP1 19 vaccines in Freund's adjuvant induced high titers of PyMSP1 19 -specific antibodies, leading to protection against lethal challenge. Although the PyMSP1 19 -specific antibodies at the time of infection are consumed to impair P. yoelii growth, no natural boosting of vaccine-induced PyMSP1 19 -specific antibody responses is elicited during infection (31) . Recent studies demonstrated that the parasite induces apoptotic deletion of vaccine-specific memory B cells, long-lived plasma cells, and CD4
ϩ T cells, resulting in failure of the naturally boosting antibody response to malaria parasites during infection (13, 32, 33) . This is supported by sero-epidemiological studies showing that a significant proportion of Africans do not possess IgG antibodies to P. falciparum MSP1 despite repeat exposure to malaria (9) (10) (11) . Thus, it is likely that malaria parasites manipulate the host's apoptotic pathway to subvert the generation and/or maintenance of immunological memory (21) . To date, however, little evidence has been documented on a host's immune response to infection, specifically regarding the natural boosting associated with vaccine-induced immune responses (26) . Most malaria vaccine studies with animal models and in human clinical trials have focused mainly on the evaluation of immunization-induced immune responses present before challenge. We hypothesize that the limited success of blood-stage vaccines in human clinical trials is mainly due to apoptosis induction of vaccine-induced memory B cells by the parasite. If so, it is essential to develop a new vaccine vector capable not only of inducing strong protective immune responses but also of circumventing the parasite-induced apoptosis of vaccinespecific immune cells.
The baculovirus Autographa californica nucleopolyhedrosis virus (AcNPV) is an enveloped, double-stranded DNA virus that naturally infects insects. AcNPV has long been used as a biopesticide and as a tool for efficient production of complex animal, human, and viral proteins that require folding, subunit assembly, and extensive posttranslational modification in insect cells (22, 23) . In recent years, AcNPV has been engineered for expression of complex eukaryotic proteins (e.g., vaccine candidate antigens) on the surface of the viral envelope (12, 17, 25, 34, 35) and has emerged as a new vaccine vector with several attractive attributes, including (i) low cytotoxicity, (ii) an inability to replicate in mammalian cells, and (iii) an absence of preexisting antibodies. AcNPV also possesses strong adjuvant properties which can activate dendritic cell (DC)-mediated innate immunity through MyD88/Toll-like receptor 9 (TLR9)-dependent and -independent pathways (1), and intranasal (i.n.) immunization with AcNPV protects mice from a lethal challenge of influenza virus through innate immune responses (2) . Therefore, nasal mucosal tissues, which are abundant in DCs and macrophages, may be attractive sites for immunization with AcNPV-based vaccines to induce TLR9-mediated immune responses.
In the present study, we describe i.n. immunization with an AcNPV-based PyMSP1 19 vaccine (AcNPV-PyMSP1 19 surf) as a model of a blood-stage vaccine and evaluate the vaccine efficacy in a murine model. Needle-free nasal drop immunization with this vaccine induced not only strong systemic humoral immune responses with high titers of PyMSP1 19 -specific antibodies but also natural boosting of PyMSP1 19 -specific antibody responses shortly after challenge, conferring complete protection. These results suggest that the needle-free nasal drop malaria vaccine based on the baculoviral vector could open a new avenue to developing a novel blood-stage malaria vaccine delivery platform. PFU) by intubation with an animal-feeding needle (Natsume, Tokyo, Japan). For each route of immunization, sera were collected and mice were challenged with 1 ϫ 10 3 live P. yoelii 17XL-parasitized red blood cells (pRBC) by intravenous (i.v.) injection 2 weeks after the final immunization. To examine the vaccine efficacy of AcNPV-PyMSP1 19 surf, the baculovirus-produced PyMSP1 19 protein may be more suitable as a reference immunogen than E. coli-produced GSTPyMSP1 19 . However, our conventional purification methods cannot remove small traces of contamination of baculovirus virions and genomic DNA, which have strong adjuvant properties to induce innate immunity. Therefore, the present study used E. coli-produced GST-PyMSP1 19 as a standard recombinant PyMSP1 19 vaccine formulated with alum. The course of parasitemia was monitored by microscopic examination of Giemsa-stained thin blood smears obtained from tail bleeds. All care and handling of the animals were in accordance with the guidelines for animal care and use prepared by Jichi Medical University.
ELISA for antibody titers and isotypes. Sera obtained from immunized mice were collected by tail bleeds 2 weeks after the final immunization, prior to challenge. For some mice, sera were also collected periodically after challenge. For PyMSP1 19 -specific antibodies of mice immunized with AcNPV-based vaccines, precoated ELISA plates with 100 ng/well GST-PyMSP1 19 were incubated with serial dilutions of sera. For PyMSP1 19 -specific antibodies of mice immunized with GST-PyMSP1 19 , precoated ELISA plates with 100 ng/well yPyMSP1 19 were incubated with serial dilutions of sera to avoid cross-reaction with GST. We confirmed that sera obtained from mice immunized with AcNPV-PyMSP1 19 surf reacted equally with GST-PyMSP1 19 and yPyMSP1 19 . For blood-stage parasitespecific antibodies, P. yoelii 17XL antigen was prepared from blood of P. yoelii 17XL-infected mice as described previously (3) . Specific IgGs were detected using horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (HϩL) (Bio-Rad, Hercules, CA). For isotype determination, HRP-conjugated rabbit anti-mouse IgM, IgG␥ (Southern Biotechnology Associates Inc., Birmingham, AL), IgG1, IgG2a, IgG2b, and IgG3 (Zymed Laboratories, San Francisco, CA) antibodies were used. The plates were developed with peroxidase substrate solution [H 2 O 2 and 2,2Ј-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)]. The optical density (OD) at 414 nm of each well was measured using a plate reader. End-point titers were expressed as the reciprocal of the highest sample dilution for which the OD was equal to or greater than the mean OD for nonimmune control sera.
Cytokine detection. Sera were collected at various times after challenge and stored at Ϫ80°C until analysis. The presence of cytokines was analyzed using the BioPlex system (Bio-Rad) as described by de Jager et al. (7) . The following cytokines were analyzed: interleukin-2 (IL-2), IL-4, IL-5, IL-10, IL-12p70, granulocyte-macrophage colony-stimulating factor (GM-CSF), gamma interferon (IFN-␥), and tumor necrosis factor alpha (TNF-␣).
Statistical analyses. Statistical analysis was performed with Graphpad Prism software (Graphpad Software Inc.). Fisher's exact probability test was used to compare the numbers of surviving animals in different groups, and the MannWhitney U test was used to compare peak levels of parasitemia between two groups. Wilcoxon and Mann-Whitney U tests were used to compare antibody levels between groups for paired and unpaired data, respectively. Spearman's rank correlation test was used to assess associations between antibody levels and maximal parasitemia. A P value of Ͻ0.05 was considered statistically significant for these analyses.
RESULTS

Construction of baculovirus-based PyMSP1 19 vaccine.
AcNPV-PyMSP1 19 surf harbored a gene cassette that consisted of the gp64 signal sequence and the Pymsp1 19 gene fused to the N terminus of the coding region for the AcNPV major envelope protein gp64 under the control of the polyhedrin promoter (Fig. 1A) . Western blot analysis showed that both anti-FLAG monoclonal antibody (MAb) and P. yoelii-hyperimmune serum recognized the PyMSP1 19 -gp64 fusion protein, at a molecular mass of 75 kDa (Fig. 1B , lanes 2 and 4, respectively). AcNPV-PyMSP1 19 surf was treated with 10-fold serial dilutions of 2-mercaptoethanol (2-ME). Reduction of the concentration of 2-ME increased the reactivity of the 75-kDa band for P. yoelii-hyperimmune serum (Fig. 1C) . In contrast, anti-FLAG MAb, which recognizes a linear epitope, retained the same reactivity of the 75-kDa band irrespective of the 2-ME concentration (Fig. 1D ). Immunoelectron microscopy showed that PyMSP1 19 was displayed on the viral envelope of AcNPV-PyMSP1 19 surf (Fig. 1E) . These results indicate that the PyMSP1 19 -gp64 fusion protein forms oligomers on the virus envelope and retains the three-dimensional structure of the native PyMSP1 19 protein with correctly formed disulfide bonds.
i.n. immunization with AcNPV-PyMSP1 19 surf induces high levels of PyMSP1 19 -specific antibody titer. i.n. immunization with AcNPV-PyMSP1 19 surf induced significantly higher PyMSP1 19 -specific antibody titer levels than did i.m. immunization (2.7-fold; P Ͻ 0.01) ( 19 surf was treated with loading buffer containing various concentrations of 2-ME. The reactivity of the PyMSP1 19 -gp64 fusion protein was examined using either P. yoelii-hyperimmune serum (C) or anti-FLAG MAb (D). The concentrations of 2-ME are shown at the top. (E and F) Electron micrographs of AcNPV-PyMSP1 19 surf displaying PyMSP1 19 on the viral envelope. AcNPV-PyMSP1 19 surf was treated with either mouse anti-GST-PyMSP1 19 antiserum (E) or normal mouse serum (F) followed by labeling with anti-mouse-gold conjugate. The surfaces of the virions were strongly labeled with gold particles (arrows). Bars, 100 nm. 19 -specific antibody responses. Sera were collected from individual mice (10 mice/group) 3 weeks after the last immunization. (A) The individual sera were tested for total IgG, IgG1, IgG2a, IgG2b, and IgG3 specific for PyMSP1 19 by ELISA. The data represent one of two experiments, which had similar results. Data are presented as means Ϯ standard deviations (SD) for the groups. Significant differences in total IgG titers between different groups were evaluated using two-tailed Fisher's exact probability test. (Fig. 2C) . Protection of mice immunized with AcNPV-PyMSP1 19 surf against challenge infection. The groups of immunized mice were challenged i.v. with lethal P. yoelii 17XL, and the course of infection was monitored (Table 1 ). All but one of the nonimmunized control mice died with high parasitemia (76%) by day 8 postchallenge. Mice immunized either i.m. or i.n. with AcNPV-WT suffered severe courses of infection with high maximum parasitemia levels (Ͼ70% parasitemia) and 100% mortality, indicating that AcNPV alone had no protective effect. In the i.m. AcNPV-PyMSP1 19 surf group, 7 of 15 mice survived after challenge, with high maximum parasitemia (mean Ϯ standard error of the mean [SEM], 51.1% Ϯ 5.1%). All mice immunized with i.n. AcNPV-PyMSP1 19 surf survived after challenge. Compared with the i.m. AcNPVPyMSP1 19 surf group, the i.n. AcNPV-PyMSP1 19 surf group experienced significantly lower maximum parasitemia levels (7.56% Ϯ 3.95%; P Ͻ 0.01) and earlier parasite clearance (14.7 Ϯ 1.4 days; P Ͻ 0.05). In the GST-PyMSP1 19 group, 7 of 15 mice survived after challenge, with moderate maximum parasitemia (37.8% Ϯ 7.2%). PyMSP1 19 -specific antibody titers were inversely related to maximal parasitemia, and reduction of parasitemia and protection from death depended upon a high titer of PyMSP1 19 -specific antibodies at challenge (Fig. 3A) . Antibody titers over 1:80,000 conferred 100% (22/22 mice) survival, while antibody titers under 1:80,000 resulted in high parasitemia and 12.5% (1/8 mice) survival. Thus, i.n. immunization with AcNPVPyMSP1 19 surf induced a solid level of protection against a lethal challenge infection. Interestingly, the protection efficacy was only 40% (2/5 mice) in the i.n GST-PyMSP1 19 -plusAcNPV-WT immunization group (Table 1) , despite high titers of PyMSP1 19 -specific antibodies (Х4 ϫ 10 5 ; predominantly IgG1 and IgG2b) (Fig. 2D) . The two surviving mice did not induce natural boosting after challenge (data not shown). i.n. immunization with GST-PyMSP1 19 alone induced very low titers of PyMSP1 19 -specific antibodies (Х6 ϫ 10 3 ; predominantly IgG1) (Fig. 2D ) and conferred no protection. These results indicate that although AcNPV itself can act as a mucosal adjuvant and induce systemic antibody responses, display of PyMSP1 19 on the surface of the viral envelope is essential to induce protective immunity. Unlike i.n. immunization, oral immunization with AcNPVPyMSP1 19 surf induced low levels of PyMSP1 19 -specific antibodies (Х4 ϫ 10 4 ; predominantly IgG1 and IgG2b) (Fig.  2D ) and conferred no protection (Table 1) .
FIG. 2. PyMSP1
Immunization with AcNPV-PyMSP1 19 surf induces natural boosting of vaccine-induced antibodies to infection. Determining if PyMSP1 19 -specific antibody responses induced by immunization were boosted in response to infection was critical to our study. When parasites were cleared, the PyMSP1 19 -specific antibody levels of the i.m. and i.n. AcNPV-PyMSP1 19 surf groups were increased 8.0-and 8.5-fold, respectively (Fig. 3B) . The PyMSP1 19 -specific antibody titer of the i.n. AcNPVPyMSP1 19 surf group at day 29 was significantly higher (P ϭ 0.014) than that of the i.m. AcNPV-PyMSP1 19 surf group, in- dicating a stronger natural boosting effect by i.n. immunization. In contrast, there was no difference in the antibody levels of the GST-PyMSP1 19 group before and after infection. Interestingly, compared with the IgG1, -2a, and -2b isotypes, which increased 2.5-to 5-fold, IgG3 levels were elevated 11-and 36-fold for i.m. and i.n. immunization, respectively (data not shown). Natural boosting of PyMSP1 19 -specific antibodies was induced during the course of infection. To examine when natural boosting of PyMSP1 19 -specific antibodies was induced, PyMSP1 19 -specific antibody titers during the course of infection were determined. The kinetics of antibody titers was plotted with the course of parasitemia (Fig. 4A) . PyMSP1 19 -specific antibodies induced by i.n. immunization with AcNPVPyMSP1 19 surf drastically increased (eightfold) during days 10 to 13 postchallenge, coinciding with the decreasing parasitemia and parasite clearance, suggesting that the quick response of natural boosting may play critical roles in effective clearance of the parasites. In contrast, the antibody levels of the GSTPyMSP1 19 group gradually declined, to 10% of prechallenge levels, from days 7 to 20 postchallenge, as high levels of parasitemia were developed. This finding also supports the demonstration that PyMSP1 19 -specific antibodies alone can control parasitemia postchallenge (31) .
We further addressed the developed antiparasite antibody titers on days 0 and 29 postchallenge. The P. yoelii-specific IgG titer was significantly increased on day 29 for both groups (Fig. 4B) , while P. yoelii-specific IgM was signifi- cantly elevated in the GST-PyMSP1 19 group but not in the i.n. AcNPV-PyMSP1 19 surf group (Fig. 4C) . These results suggest that the increasing P. yoelii-specific IgG in the i.n. AcNPV-PyMSP1 19 surf group were mainly due to natural boosting of PyMSP1 19 -specific antibodies against native PyMSP1 19 on merozoites, resulting in effective parasite clearance. The increase in P. yoelii-specific IgM in the GST-PyMSP1 19 group during infection was likely due to primary immune responses to parasite antigens other than PyMSP1 19 . For blood-stage parasites, the magnitudes, kinetics of production, and overall balance of proinflammatory and anti-inflammatory cytokines are critically important to infection outcome. We monitored cytokine expression profiles with parasitemia in immunized mice during the course of infection (Fig. 4D to F) . Much lower levels of proinflammatory (TNF-␣) and anti-inflammatory (IL-5 and IL-10) cytokines were induced in the sera of the i.n. AcNPV-PyMSP1 19 surf group than in those of the GST-PyMSP1 19 group. Thus, i.n. immunization with AcNPV-PyMSP1 19 surf circumvented cytokine dysregulation caused by high parasitemia.
TLR9 is involved in the mechanism of protection by i.n. immunization with AcNPV-PyMSP1 19 surf. To determine the role of TLR9 in the AcNPV-PyMSP1 19 surf-induced protection, TLR9-deficient mice on a BALB/c background were immunized and challenged with P. yoelii 17XL as described above. Significantly lower levels of PyMSP1 19 -specific antibody titers were induced in TLR9-deficient mice immunized with i.n. AcNPV-PyMSP1 19 surf and GST-PyMSP1 19 in alum than in the corresponding normal BALB/c mouse groups (Fig. 5A) . The IgG isotype in the i.m. and i.n. AcNPV-PyMSP1 19 surf groups was mainly IgG1 (IgG1/IgG2a ratio Х 4.36 and 5.39, respectively), and IgG3 antibody was undetectable (Ͻ1:100) in any group (Fig. 5B) . Thus, Th2 immune responses are induced in TLR9-deficient mice, completely contrasting with the mixed Th1/Th2-type immune responses of normal BALB/c mice shown in Fig. 2A .
During challenge, the protection efficacy for each immunized group was almost abolished in TLR9-deficient mice (Table 2). Even though the immunized mice had high antibody titers (Ն8 ϫ 10 4 ), 82% (14/17 animals) of mice died with high parasitemia (Ͼ60%). The three surviving mice from each group did not induce natural boosting of PyMSP1 19 -specific antibodies in response to infection.
DISCUSSION
In the present study, we developed a new PyMSP1 19 Mucosal immunization induces antigen-specific Th1-and/or Th2-type immune responses, depending on the nature of the antigen, adjuvant, and antigen delivery vehicle used. Although both i.m. and i.n. immunizations with AcNPV-PyMSP1 19 surf induced a mixed Th1/Th2-type immune response, i.n. immunization led to higher PyMSP1 19 -specific antibody titers and stronger natural boosting after challenge than did i.m. immunization. The i.n. immunization with GST-PyMSP1 19 plus AcNPV-WT induced high levels of PyMSP1 19 -specific IgG1 and IgG2b titers and protected 40% (2/5 mice) of mice against challenge, but no natural boosting was induced. When cholera toxin B was used as a mucosal adjuvant with rPyMSP1 19 , a Th2-type immune response (predominantly IgG1 and IgG2b) was induced, and 38% (3/8 mice) of mice were protected against challenge (14) . Thus, the protection efficacy (100%) of i.n. immunization with AcNPV-PyMSP1 19 surf was superior to those of other nasal immunization regimens. This suggests that i.n. immunization with AcNPV-PyMSP1 19 surf displaying PyMSP1 19 on the surface of the viral envelope would be essential for inducing Th1 cell-derived IFN-␥ production, which determines switching to IgG2a as a consequence of the cognate interaction of B cells with Th1 cells (4) .
The source of Th1 cells and the precise mechanism of natural boosting are not yet defined. It is possible that i.n. immunization with AcNPV-PyMSP1 19 surf activated DCs and macrophages, which are abundant in nasal passage-associated lymphoid tissue (NALT), a mucosal inductive site in the upper respiratory tract for humoral and cellular immune responses (36) , through a TLR9-dependent pathway. In fact, AcNPV itself (composed of viral genomic DNA containing abundant CpG motifs) possesses strong adjuvant properties which can activate DC-mediated innate immunity through MyD88/ TLR9-dependent and -independent pathways (1). The present study provides important insights into the roles of TLR9 following immunization with AcNPV-PyMSP1 19 surf. In the TLR9-deficient mice immunized with AcNPV-PyMSP1 19 surf, class switching to IgG2a was severely impaired, and natural boosting and protective efficacy were completely abolished. Jegerlehner et al. showed that IFN-␥-independent IgG2a class switching is regulated by direct TLR9 signaling in B cells (16) . It is likely that AcNPV-PyMSP1 19 surf-induced natural boosting after challenge is associated with a TLR9-dependent pathway, and direct stimulation of B cells by AcNPV-PyMSP1 19 surf (after the second and third immunizations) could be the driving factor for class switch recombination to IgG2a in NALT. Nasal drop vaccines have several attractive features compared with parenteral vaccines (e.g., safety, cost-effectiveness, and ease of administration), but studies on their use have been limited almost exclusively to protection against mucosally transmitted pathogens. We have provided evidence that i.n. immunization is a feasible alternative for preventing malaria transmitted through nonmucosal routes. Further studies are necessary to fully understand the responses of antigen-presenting cells (APCs) in the NALT (mice) and Waldeyer's ring (humans), consisting of the adenoids and tonsils (20) , to AcNPV.
Although 8 of 14 TLR9-deficient mice immunized with GST-PyMSP1 19 in alum had high (Ͼ8 ϫ 10 4 ) anti-PyMSP1 19 antibody titers (Table 2) , which are sufficient for normal mice immunized with GST-PyMSP1 19 to suppress parasite growth, all mice died with high parasitemia. The failure of protection suggests another role of TLR9. It has been reported that blood-stage parasites activate DCs through a TLR9-dependent pathway (27) . In addition, we observed that unlike normal BALB/c mice, TLR9-deficient mice passively immunized with anti-PyMSP1 19 antibody died with high parasitemia when challenged with P. yoelii 17XL (data not shown). Thus, TLR9 may enhance antigen presentation by DCs, resulting in induction of antibody responses to parasite antigens during the course of infection. Further studies of TLR9-mediated memory B-cell responses to baculovirus-based vaccines and natural human malaria infection are needed.
Needle-free nasal drop immunization with the baculovirusbased vaccine provides important insights into (i) enhancement of immunogenicity of PfMSP1 42 , (ii) strong adjuvant effects through TLR9, and (iii) subsequent natural boosting to improve current PfMSP1 42 -based vaccine candidates. 
